In contrast, the only solid tumors with noticeable sensitivity to venetoclax were SCLC and MYCN-amplified neuroblastoma [13,35,36], and there is an on-going clinical trial with venetoclax for neuroblastoma (NCT04029688). This evidence concerns the gene MYCN and small cell lung carcinoma.